Sugi Predict

Sugi Predict / Compounds / SCHEMBL2921464

SCHEMBL2921464

SCHEMBL2921464

CC(C)(C)OC(=O)N1CCOC(CC(=O)O)C1

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.50
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ RECQL P46063 1/20 0.45
▸ NR1H2 P55055 1/20 0.41
▸ MAPT P10636 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ PDK1 Q15118 3/20 0.40
▸ EPHA2 P29317 4/20 0.40
▸ KDM4E B2RXH2 1/20 0.39
▸ THRB P10828 1/20 0.39
▸ ERBB2 P04626 1/20 0.38
▸ EPHB4 P54760 1/20 0.38
▸ USP30 Q70CQ3 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ JAK2 O60674 1/20 0.37
▸ JAK1 P23458 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22370245 1.00 USP2 (0.50) USP2SMN1; SMN2RECQLNR1H2MAPT
SCHEMBL22370549 1.00 USP2 (0.50) USP2SMN1; SMN2RECQLNR1H2MAPT
SCHEMBL25146707 0.92 MAPT (0.47) USP2SMN1; SMN2RECQLNR1H2MAPT
SCHEMBL29878090 0.87 RECQL (0.53) USP2SMN1; SMN2RECQLMAPTKDM4E
SCHEMBL31479364 0.87 USP2 (0.49) USP2SMN1; SMN2RECQLNR1H2MAPT
SCHEMBL18259594 0.86 USP2 (0.48) USP2SMN1; SMN2RECQLNR1H2MAPT
SCHEMBL18259593 0.86 USP2 (0.48) USP2SMN1; SMN2RECQLNR1H2MAPT
SCHEMBL31479278 0.86 USP2 (0.48) USP2SMN1; SMN2RECQLNR1H2MAPT
SCHEMBL304804 0.85 USP2 (0.53) USP2SMN1; SMN2RECQLNR1H2MAPT
SCHEMBL553919 0.85 USP2 (0.53) USP2SMN1; SMN2RECQLNR1H2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4430042-B1 6-HETERO ARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS INC (US) 2026-02-18 — — EP disclosed
WO-2025120611-A1 ANTIPARASITIC COMPOUNDS ANIMOL DISCOVERY, INC. (US) 2025-06-12 — — WO disclosed
EP-4430042-A1 6-HE TERO ARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. (US) 2024-09-18 — — EP disclosed
US-20240254125-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS AJAX THERAPEUTICS, INC. 2024-08-01 — — US disclosed
WO-2024140736-A1 TRIPEPTIDE EPOXY KETONE COMPOUND, PHARMACEUTICAL COMPOSITION, AND PREPARATION METHOD THEREFOR AND USE THEREOF 上海美悦生物科技发展有限公司 2024-07-04 — — WO disclosed
CN-118201928-A 6-Heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors 艾捷斯治疗公司 2024-06-14 — — CN disclosed
CN-117999263-A SOS1 inhibitor with pyrido six-membered ring structure 上海海和药物研究开发股份有限公司 2024-05-07 — — CN disclosed
US-11970494-B2 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors AJAX THERAPEUTICS, INC. (US) 2024-04-30 — — US disclosed
US-20230167110-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS SCHRÖDINGER, INC. 2023-06-01 — — US disclosed
US-20230167110-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS SCHRÖDINGER, INC. 2023-06-01 — — US disclosed
US-20120214759-A1 TREATMENT OF KLEBSIELLA PNEUMONIAE INFECTIONS WITH ANTIBACTERIAL AMINOGLYCOSIDE COMPOUNDS ACHAOGEN, INC. (US) 2012-08-23 — — US disclosed
CN-102481307-A Treatment of klebsiella pneumoniae infections with antibacterial aminoglycoside compounds ACHAOGEN INC 2012-05-30 — — CN disclosed
CN-102481306-A Treatment of urinary tract infections with antibacterial aminoglycoside compounds ACHAOGEN INC 2012-05-30 — — CN disclosed
WO-2010132777-A2 TREATMENT OF URINARY TRACT INFECTIONS WITH ANTIBACTERIAL AMINOGLYCOSIDE COMPOUNDS ACHAOGEN, INC. (US) 2010-11-18 — — WO disclosed
WO-2010132770-A1 TREATMENT OF KLEBSIELLA PNEUMONIAE INFECTIONS WITH ANTIBACTERIAL AMINOGLYCOSIDE COMPOUNDS ACHAOGEN, INC. (US) 2010-11-18 — — WO disclosed
CN-101868472-A Antibacterial aminoglycoside analogs ACHAOGEN INC 2010-10-20 — — CN disclosed
EP-2217610-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS Achaogen, Inc. (US) 2010-08-18 — — EP disclosed
US-20100099661-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS ACHAOGEN, INC. (US) 2010-04-22 — — US disclosed
WO-2009067692-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS ACHAOGEN, INC. (US) 2009-05-28 — — WO disclosed
CN-101014595-A Novel cyclic aminobenzoic acid derivative KYORIN SEIYAKU KK (JP) 2007-08-08 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11970494-B2 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors JAK2, JAK3, STAT5B USP2 1173/4885SMN1; SMN2 4718/4885RECQL 3095/4885
US-20100099661-A1 ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS MRPL21, MRPL9, NQO2 USP2 3805/4885SMN1; SMN2 2895/4885RECQL 7/4885
US-20230167110-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS JAK2, JAK3, STAT5B USP2 1173/4885SMN1; SMN2 4718/4885RECQL 3095/4885
US-20240254125-A1 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS JAK2, JAK3, STAT5B USP2 1173/4885SMN1; SMN2 4718/4885RECQL 3095/4885
US-20120214759-A1 TREATMENT OF KLEBSIELLA PNEUMONIAE INFECTIONS WITH ANTIBACTERIAL AMINOGLYCOSIDE COMPOUNDS PIGS, PIGO, NPEPPS USP2 2774/4885SMN1; SMN2 4076/4885RECQL 2769/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback